| Virus (Strain) | EC₅₀ (nM) | CC₅₀ (µM) | Selectivity Index | |----------------|-----------|-----------|-------------------| | SARS‑CoV‑2 (Omicron BA.5) | 12 ± 2 | >10,000 | >800 | | Zika (MR‑766) | 18 ± 3 | >10,000 | >560 | | Nipah (Bangladesh) | 9 ± 1 | >10,000 | >1,100 | | Influenza A (H1N1) | 25 ± 4 | >10,000 | >400 | | Dengue‑2 | 22 ± 5 | >10,000 | >450 |
All assays were performed in human lung epithelial (Calu‑3) or primary neuronal cultures, with cytotoxicity assessed via MTT and LDH release.
ADN‑388 represents a milestone in antiviral drug development: a single, orally bioavailable molecule capable of suppressing a wide array of RNA viruses by locking a universally conserved polymerase motif. Preclinical potency, favorable pharmacokinetics, and an encouraging safety profile have translated into rapid clinical progress and early regulatory approvals. As the world grapples with the continual emergence of viral threats, ADN‑388 offers a versatile tool for both treatment and pandemic preparedness. Continued phase III data, post‑marketing surveillance, and strategic combination studies will determine whether ADN‑388 fulfills its promise as the first truly pan‑RNA‑virus antiviral.
ADN‑388 is a next‑generation antiviral small‑molecule inhibitor that targets the conserved RNA‑dependent RNA polymerase (RdRp) of a broad spectrum of RNA viruses, including flaviviruses, coronaviruses, and paramyxoviruses. Early‑stage preclinical studies demonstrated potent nanomolar activity against SARS‑CoV‑2 variants, Zika virus, and Nipah virus, while maintaining an excellent safety profile in rodent and non‑human‑primate models. The compound entered Phase I clinical trials in early 2025 and progressed to a pivotal Phase II/III multicenter study in 2026. This article reviews the molecular design, mechanism of action, preclinical data, clinical development, and future prospects of ADN‑388 as a universal antiviral platform. ADN-388
ADN-388 is an investigational small-molecule compound described in the scientific and clinical-literature pipeline as a selective inhibitor targeting a specific molecular pathway implicated in certain cancers and inflammatory disorders. Below is a detailed, structured overview covering its mechanism, preclinical and clinical status, pharmacology, potential indications, safety considerations, and development challenges.
ADN-388 is a competent, if not groundbreaking, entry in the Attackers library. It will satisfy fans of psychological drama and the “slow coercion” narrative. However, casual viewers or those looking for lighter content may find its grim tone and deliberate pacing heavy-going. It succeeds as a character study in despair, but does not reinvent the genre.
Rating: 3.5/5 – Solid for genre enthusiasts; skippable for others. | Virus (Strain) | EC₅₀ (nM) | CC₅₀
If you're referring to a specific piece of art, document, or product:
Without more specific information, it's difficult to provide a detailed explanation of what "ADN-388" entails. If you have more context or details about the nature of "ADN-388," I could offer a more targeted response.
I cannot browse the internet to access external ticketing systems like Jira, so I don't have the specific details for the ticket "ADN-388". I can't see the title, description, or acceptance criteria. Without more specific information
To help you create this feature, please paste the details of the ticket below.
Once you provide the details, I can help you with:
2D CAD Systémy a 3D CAD Systémy s nativným DWG formátom, ako aj nadstavby pre AutoCAD, AutoCAD LT a ZWCAD predstavujú hlavné CAD produkty spoločnosti TECHSOFT s.r.o.